Sucralfate NDC 72578-081

NDC codes

FDA NDC Directory

Product NDC (as listed)72578-081Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72578-0081Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
72578-081-01	72578008101	100 TABLET in 1 BOTTLE (72578-081-01)Marketed from May 20, 2023
72578-081-05	72578008105	500 TABLET in 1 BOTTLE (72578-081-05)Marketed from May 20, 2023
72578-081-06	72578008106	30 TABLET in 1 BOTTLE (72578-081-06)Marketed from May 20, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sucralfate
Generic name (nonproprietary): sucralfate
Active ingredients: Sucralfate — 1 g/1
Dosage form: Tablet
Route: Oral
Labeler: Viona Pharmaceuticals Inc
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215705
Marketing start: May 20, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Organometallic Compounds (Chemical structure)
Identifiers: Product ID 72578-081_dd615804-6bb1-4c0a-bafb-7f6c27c55df4SPL ID dd615804-6bb1-4c0a-bafb-7f6c27c55df4SPL set ID c708201b-2618-4470-a3ff-8ecf04d6b3a0RxCUI 314234UNII XX73205DH5
Pharmacologic class: Aluminum Complex

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472578008101 followed by a unit qualifier and the quantity

Package 72578-0081-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 8, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Sucralfate tablets are indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215705

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215705
Product	Strength	Form · route	Labeler	Product NDC
Sucralfate	Sucralfate 1 g/1	TabletOral	Redpharm Drug	67296-2147
Sucralfate	Sucralfate 1 g/1	TabletOral	Coupler LLC	67046-1469
Sucralfate	Sucralfate 1 g/1	TabletOral	Preferred Pharmaceuticals Inc	68788-8779
Sucralfate	Sucralfate 1 g/1	TabletOral	NCS HealthCare of KY, LLC dba Vangard Labs	0615-8653
Sucralfate	Sucralfate 1 g/1	TabletOral	Bryant Ranch Prepack	71335-2461
Sucralfate	Sucralfate 1 g/1	TabletOral	Zydus Lifesciences Limited	70771-1833
Sucralfate	Sucralfate 1 g/1	TabletOral	NuCare Pharmaceuticals, Inc.	68071-3812